The MHRA has also granted approval to Faron Pharmaceuticals to conduct the BEXMAB trial of Clevegen in the UK.

The research team at UQ has secured a grant of $344,000 from the National Foundation for Medical Research and Innovation.

The EMA’s CHMP has endorsed expanding the use of Palforzia to toddlers aged one to three years with peanut allergies.

Fate has announced the retirement of president and CEO Scott Wolchko with Bob Valamehr set to assume the role from 1 January ...

CBC Group has completed the strategic acquisition of UCB's mature neurology and allergy business in China for $680m.

Allink Biotherapeutics has completed a $42m Series A financing round to expedite the worldwide development of its bispecific ...

The HIV vaccine space has seen dwindling research activity as drug manufacturers turn to PrEP therapies for preventive ...

The US Food and Drug Administration has declined to approve Applied Therapeutics’ govorestat for classic galactosemia.

The relationship between climate change and infectious disease is raising new questions for pharmaceutical and clinical ...

University of Birmingham researchers have identified CD70 as a key target to reduce the risk of GVHD in blood cancer patients ...

This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...

Meningitis C cases are down 99% since the NHS routine vaccination programme was introduced by UKHSA and NHS England in 1999.